Valuation
- Market cap
- 258,248,000
- Revenue TTM
- $0
- Net income TTM
- $-102,020,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 1.46
Trading
- Volume
- 1,459,400
- Avg volume
- 2,648,666
- Day's range
- $3.99 – $4.00
- Shares out
- 64,562,000
- Stochastic %K
- 100%
- Beta
- 2.27
- Analysts
- Hold
- Price target
- $5.40
Company profile
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving he...
Show more
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 330 4340
- Website
- https://www.inozyme.com
- Address
- 321 Summer Street, Suite 400, Boston, United States
Latest news
No headlines yet.
